These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37875235)

  • 1. Early Initiation of PCSK9 Inhibitor Therapy Versus Placebo in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
    Justino GB; Justino LB; Müller ME; Rocha AV; Mazetto A; Cardoso R; Leucker TM
    Am J Cardiol; 2024 Feb; 213():110-118. PubMed ID: 37875235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis.
    Nagendra L; Mahajan K; Gupta G; Dutta D
    Indian Heart J; 2023; 75(6):416-422. PubMed ID: 37777180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
    Schwartz GG; Giugliano RP
    Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
    Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
    PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
    Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-hospital initiation of a PCSK9 inhibitor in patients with acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials.
    Shi W; Xu Y; Zhou L; Wang W; Huang W; Zhou B
    Medicine (Baltimore); 2024 Mar; 103(10):e37416. PubMed ID: 38457555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?
    Canonico ME; Hess CN; Cannon CP
    Curr Atheroscler Rep; 2023 Jul; 25(7):381-389. PubMed ID: 37223853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients.
    Jin ZL; He T; Peng L; Wu XY; Fan D; Chen M; Fan YZ; Guo YL; Lu ZB; Wang HR
    Curr Med Sci; 2023 Dec; 43(6):1206-1212. PubMed ID: 37755635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis.
    Mahajan K; Nagendra L; Dhall A; Dutta D
    Eur J Intern Med; 2024 Jun; 124():99-107. PubMed ID: 38336550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG; Steg PG; Szarek M; Bittner VA; Diaz R; Goodman SG; Kim YU; Jukema JW; Pordy R; Roe MT; White HD; Bhatt DL;
    Circulation; 2020 May; 141(20):1608-1617. PubMed ID: 32223446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice.
    Sabouret P; Puymirat E; Kownator S; Abdennbi K; Lebeau F; Meltz M; Angoulvant D; Schiele F
    Panminerva Med; 2023 Jun; 65(2):244-249. PubMed ID: 36222543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid management in ACS: Should we go lower faster?
    Gencer B; Mach F
    Atherosclerosis; 2018 Aug; 275():368-375. PubMed ID: 30015301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
    Hagström E; Steg PG; Szarek M; Bhatt DL; Bittner VA; Danchin N; Diaz R; Goodman SG; Harrington RA; Jukema JW; Liberopoulos E; Marx N; McGinniss J; Manvelian G; Pordy R; Scemama M; White HD; Zeiher AM; Schwartz GG;
    Circulation; 2022 Aug; 146(9):657-672. PubMed ID: 35770629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials.
    Benhuri B; Ueyama H; Takagi H; Briasoulis A; Kuno T
    Curr Vasc Pharmacol; 2021; 19(4):390-397. PubMed ID: 32767943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
    Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
    Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome.
    Sarak B; Savu A; Kaul P; McAlister FA; Welsh RC; Yan AT; Goodman SG
    Circ Cardiovasc Qual Outcomes; 2021 Apr; 14(4):e006646. PubMed ID: 33813856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.
    Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B
    JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
    Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
    Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation.
    LaFratte C; Peasah SK; Huang Y; Hall D; Patel U; Good CB
    J Am Heart Assoc; 2023 Sep; 12(18):e029707. PubMed ID: 37702065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.